John M. Evans, CEO at Beam Therapeutics Inc. (BEAM), sold 109,800 shares at $68.15 ($6.5M) on 2022-01-31, disclosed to the SEC on 2022-02-02.
Open-market sale of $6.5M BEAM by CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 12,000 | $0 | 0.0% |
| 2 | $63.45 | 300 | $19K | 0.3% |
| 3 | $63.79 | 801 | $51K | 0.8% |
| 4 | $63.79 | 801 | $51K | 0.8% |
| 5 | $64.46 | 1,615 | $104K | 1.6% |
| 6 | $64.46 | 1,615 |
| $104K |
| 1.6% |
| 7 | $64.47 | 2,172 | $140K | 2.1% |
| 8 | $64.47 | 2,172 | $140K | 2.1% |
| 9 | $65.49 | 3,177 | $208K | 3.2% |
| 10 | $65.49 | 3,177 | $208K | 3.2% |
| 11 | $65.55 | 1,900 | $125K | 1.9% |
| 12 | $66.48 | 4,105 | $273K | 4.2% |
| 13 | $66.48 | 4,105 | $273K | 4.2% |
| 14 | $66.55 | 6,337 | $422K | 6.4% |
| 15 | $66.55 | 6,337 | $422K | 6.4% |
| 16 | $67.43 | 9,408 | $634K | 9.7% |
| 17 | $67.43 | 9,408 | $634K | 9.7% |
| 18 | $67.44 | 13,535 | $913K | 14.0% |
| 19 | $67.44 | 13,535 | $913K | 14.0% |
| 20 | $68.15 | 3,978 | $271K | 4.1% |
| 21 | $68.15 | 3,978 | $271K | 4.1% |
| 22 | $68.16 | 2,672 | $182K | 2.8% |
| 23 | $68.16 | 2,672 | $182K | 2.8% |
| Total | $59.56 avg | 109,800 | $6.5M | 100% |
| Filing → |
| BEAM | SELL | 2026-04-01 | $1.1M | — | Filing → |
| BEAM | SELL | 2026-02-02 | $2.8M | — | Filing → |
| BEAM | SELL | 2025-10-03 | $1.2M | — | Filing → |